ZYUS Life Sciences Corporation

ZYUS Life Sciences Corporation is a clinical-stage life sciences company headquartered in Saskatoon, Saskatchewan, Canada, focused on the global development and commercialization of novel non-opioid pharmaceutical drug candidates for pain management. The company's mission is to secure intellectual property protection, obtain regulatory approval for its cannabinoid-based pharmaceutical solutions, and ultimately make a transformative impact on patients' lives by advancing the science of well-being and bringing phyto-therapeutics to the global medical market.

ZYUS's key product development centers around Trichomylin® softgel capsules, its lead drug candidate, which is being developed to treat chronic pain and inflammation, particularly for moderate to severe cancer-related pain. Beyond its proprietary drug candidates, the company also commercializes non-proprietary foundational products such as cannabinoid oils, softgel capsules, and topical creams in Canada and other international markets where medical cannabis is legal. The company operates in Canada, the United States, Australia, and the European Union.

In recent news, ZYUS Life Sciences Corporation announced in April 2026 the completion of the final study visit by the last patient in its Phase 2a UTOPIA-1 trial, which evaluates Trichomylin® softgel capsules for cancer-related pain. Brent Zettl serves as the President and CEO, leading the company's strategic direction. The company is currently positioned as a highly speculative, pre-revenue biotechnology firm, with its business model reliant on the successful development and regulatory approval of patent-protected, cannabinoid-based prescription drugs for pain, necessitating ongoing external funding for its clinical trials.